Gov. Gavin Newsom recently signed into law the California Food Safety Act and amendments to the 2020 Toxic-Free Cosmetics Act. Together, they ban four additives commonly used in popular snacks and beverages, and an additional 26 chemicals found in many personal care products.

Read on for details about these developments impacting food and personal care manufacturers, distributors and retailers.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Amy Morrissey Turk Amy Morrissey Turk

Amy Morrissey Turk is co-leader of McGuireWoods’ consumer products and retail industry team. She works on complex class actions and mass arbitrations throughout the country for companies in a variety of industries, most notably the retail, health care, and financial services industries. Amy…

Amy Morrissey Turk is co-leader of McGuireWoods’ consumer products and retail industry team. She works on complex class actions and mass arbitrations throughout the country for companies in a variety of industries, most notably the retail, health care, and financial services industries. Amy offers clients a broad spectrum of legal experience gained both as a seasoned litigator for business-focused law firms and also as a former assistant general counsel who managed the nationwide employment portfolio of a multibillion-dollar Fortune 150 retail corporation. In that in-house role, she led and directed internal investigations and the company’s litigation strategy in employment matters pending before arbitrators, agencies at all governmental levels, and state and federal courts throughout the United States. She has extensive experience managing nationwide class, collective, and mass claims.

Photo of Trent Taylor Trent Taylor

Trent, co-leader of McGuireWoods’ Food & Beverage Industry Team, focuses on defending complex class actions with an emphasis on product liability matters, public and private nuisance litigation, environmental contamination suits, and food, cosmetic, and supplement labeling (including CBD) and safety issues.

Photo of Allyson M. Maur Allyson M. Maur

Allyson advises on regulatory issues affecting diagnostics developers, biopharma manufacturers, and clinical laboratories, including CLIA/CLEP and FDA regulatory advice, MLR and MRC review of marketing and promotional materials, clinical studies, global data privacy issues, ethics & compliance, commercial contracting, commercial litigation and more.